Lakefront Biotherapeutics NV (MEX:GLPGN) Beneish M-Score: 0.58 (As of Aug. 09, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:GLPGN Lakefront Biotherapeutics NV MEX:GLPGN
58 GF Score
Price MXN665.65
GF Value MXN3,143.44
! 4 Warning Signs
View Full Analysis

What is Lakefront Biotherapeutics NV Beneish M-Score?

Lakefront Biotherapeutics NV MEX:GLPGN 58 Beneish M-Score is 0.58 as of Aug. 09, 2026. GuruFocus rates MEX:GLPGN with a GF Score™ of 58/100 and a GF Value™ of MXN3,143.44. The stock has 4 warning signs investors should review. Among 821 Biotechnology companies, Lakefront Biotherapeutics NV ranks worse than 83.92% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 0.58 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Lakefront Biotherapeutics NV's Beneish M-Score or its related term are showing as below:

MEX:GLPGN' s Beneish M-Score Range Over the Past 10 Years
Min: -4.24   Med: -1.45   Max: 33.95
Current: 0.58

During the past 13 years, the highest Beneish M-Score of Lakefront Biotherapeutics NV was 33.95. The lowest was -4.24. And the median was -1.45.


Lakefront Biotherapeutics NV Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Lakefront Biotherapeutics NV's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lakefront Biotherapeutics NV Beneish M-Score Chart

Lakefront Biotherapeutics NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.53 -1.14 -1.91 -1.33 0.57

Lakefront Biotherapeutics NV Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.48 -2.63 -2.72 0.57 0.58

MEX:GLPGN vs VRTX, REGN, RVMD: Beneish M-Score Comparison

For the Biotechnology subindustry, Lakefront Biotherapeutics NV's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lakefront Biotherapeutics NV Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lakefront Biotherapeutics NV's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Lakefront Biotherapeutics NV's Beneish M-Score falls into.


MEX:GLPGN
58GF Score
Lakefront Biotherapeutics NV MEX:GLPGN
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lakefront Biotherapeutics NV Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Lakefront Biotherapeutics NV for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.1699+0.528 * 0.8589+0.404 * 0.6416+0.892 * 3.5896+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.2588+4.679 * 0.28936-0.327 * 0.2822
=0.56

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was MXN1,126 Mil.
Revenue was 135.11 + 18992.893 + 1532.15 + 1417.902 = MXN22,078 Mil.
Gross Profit was 35.065 + 18983.3 + 1298.627 + 1315.698 = MXN21,633 Mil.
Total Current Assets was MXN63,807 Mil.
Total Assets was MXN70,305 Mil.
Property, Plant and Equipment(Net PPE) was MXN1,604 Mil.
Depreciation, Depletion and Amortization(DDA) was MXN0 Mil.
Selling, General, & Admin. Expense(SGA) was MXN2,210 Mil.
Total Current Liabilities was MXN2,094 Mil.
Long-Term Debt & Capital Lease Obligation was MXN101 Mil.
Net Income was 302.115 + 16490.733 + -4351.602 + -2296.598 = MXN10,145 Mil.
Non Operating Income was 1339.235 + 202.617 + -4071.25 + -1233.237 = MXN-3,763 Mil.
Cash Flow from Operations was -1725.094 + -1000.666 + -1347.976 + -2362.467 = MXN-6,436 Mil.
Total Receivables was MXN1,847 Mil.
Revenue was 1658.264 + 1648.692 + 1307.93 + 1535.674 = MXN6,151 Mil.
Gross Profit was 1354.62 + 1304.977 + 1307.515 + 1209.166 = MXN5,176 Mil.
Total Current Assets was MXN76,798 Mil.
Total Assets was MXN88,953 Mil.
Property, Plant and Equipment(Net PPE) was MXN2,504 Mil.
Depreciation, Depletion and Amortization(DDA) was MXN0 Mil.
Selling, General, & Admin. Expense(SGA) was MXN2,379 Mil.
Total Current Liabilities was MXN9,666 Mil.
Long-Term Debt & Capital Lease Obligation was MXN172 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(1126.45 / 22078.055) / (1846.546 / 6150.56)
=0.051021 / 0.300224
=0.1699

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(5176.278 / 6150.56) / (21632.69 / 22078.055)
=0.841595 / 0.979828
=0.8589

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (63807.343 + 1604.181) / 70305.203) / (1 - (76797.96 + 2504.194) / 88953.271)
=0.069606 / 0.108496
=0.6416

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=22078.055 / 6150.56
=3.5896

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 2504.194)) / (0 / (0 + 1604.181))
=0 / 0
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(2209.974 / 22078.055) / (2379.195 / 6150.56)
=0.100098 / 0.386826
=0.2588

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((101.129 + 2093.544) / 70305.203) / ((172.225 + 9666.068) / 88953.271)
=0.031216 / 0.110601
=0.2822

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(10144.648 - -3762.635 - -6436.203) / 70305.203
=0.28936

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Lakefront Biotherapeutics NV has a M-score of 0.56 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of 0.58 mean?
Lakefront Biotherapeutics NV (MEX:GLPGN) has a Beneish M-Score of 0.58 as of Aug. 09, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Lakefront Biotherapeutics NV and its competitors. According to the industry distribution chart, Lakefront Biotherapeutics NV ranks #689 out of 821 companies in the Biotechnology industry, placing it in the top 83.9%.
Is Lakefront Biotherapeutics NV's Beneish M-Score too high?
Lakefront Biotherapeutics NV's current Beneish M-Score is 0.58. Based on the distribution chart, Lakefront Biotherapeutics NV ranks #689 out of 821 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lakefront Biotherapeutics NV has a GF Score™ of 58/100, reflecting its overall financial health beyond just this single metric.
How does Lakefront Biotherapeutics NV's Beneish M-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lakefront Biotherapeutics NV ranks #689 out of 821 companies for Beneish M-Score. This places Lakefront Biotherapeutics NV in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Lakefront Biotherapeutics NV and its competitors. Lakefront Biotherapeutics NV's current Beneish M-Score is 0.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lakefront Biotherapeutics NV stock overvalued right now?
Lakefront Biotherapeutics NV (MEX:GLPGN) has a current Beneish M-Score of 0.58. The stock's GF Value™ is MXN3,143.44, compared to a current price of MXN665.65 — trading 78.8% below its estimated fair value. The current Beneish M-Score is 0.58. Lakefront Biotherapeutics NV's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Lakefront Biotherapeutics NV (MEX:GLPGN), the current Beneish M-Score is 0.58 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lakefront Biotherapeutics NV (MEX:GLPGN) Overvalued in 2026?

Based on GuruFocus' analysis, Lakefront Biotherapeutics NV stock appears to be undervalued. The current stock price of MXN665.65 is trading 78.8% below its estimated GF Value™ of MXN3,143.44.

Key valuation signals for MEX:GLPGN:

  • Beneish M-Score: 0.58
  • GF Value™: MXN3,143.44 vs. price of MXN665.65 (78.8% below fair value)
  • GF Score™: 58/100 with 4 warning signs

No single metric tells the full story. See the MEX:GLPGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lakefront Biotherapeutics NV Business Description

Address Schalienhoevedreef 20 T, Mechelen, BEL, 2800
Lakefront Biotherapeutics NV a biopharmaceutical company committed to improving the lives of people with severe diseases. It focuses on delivering medicines with transformational impact for patients by accelerating life-changing science and innovation in areas of high unmet need. Its pipelines includes GLPG3667, GLPG5101, and GLPG5301.
58GF Score

Get the complete analysis for MEX:GLPGN

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN665.65
Price
MXN3,143.44
GF Value